Skip to content
lifestyle.tasteterminal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Scynexis
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 24, 2026
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 23, 2026
←
Previous Page
1
2